QuVa buys New Jersey manufacturing plant citing access to regional markets

By Gareth Macdonald contact

- Last updated on GMT

QuVa HQ in Texas (Google maps)
QuVa HQ in Texas (Google maps)

Related tags: Pharmacology

QuVa Pharma has agreed to buy a manufacturing facility in New Jersey, US at which it plans to compound sterile pharmaceutical products for hospitals.

The Texas compounder announced the deal last week, explaining that the facility will allow it to access key regional markets.

The firm said it plans to make modifications and register the compounding facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act). It also said it plans to hire 100 staff when the site is operational next year.

Further details of the deal were not disclosed.

A spokesman for the firm told us "We are not permitted to say which company QuVa is purchasing the building from​."

503b plants 

QuVa currently operates two 503B compounding facilities. One of the facilities - in Sugarland, Texas – was acquired from Healix in August​ last year in a deal that also saw QuVa hire staff employed at the site.

QuVa’s other facility in Temple Texas was purchased in November when the firm acquired Unique Pharmaceuticals.

At the time QuVa said the deal was designed to increase its capacity to make sterile injectable products for hospitals

Peter Jenkins, co-founder, said: “This acquisition broadens our catalogue of available compounded products, and gives us the capability to compound preparations from API to meet supply shortages.​”

The US Food and Drug Administration (FDA) introduced the facility registration rules​ in 2013 after 64 people in 2012 as a result of contaminated drugs produced at Massachusetts firm NECC.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Related suppliers

Follow us


View more